Designs and develops bio-based polymers using itaconic acid as a core building block. Manufactures and sells these specialized polymers for various applications. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 43% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 2.9× for every dollar of annual revenue.
No analyst target is on record for this company.
The stock trades 52% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 43% a year on average.
Sales run at $10.7M a year. A small number, but proof the product has real buyers.
There is $4.4M in the vault; even if every debt were paid off, $2.4M would remain.
A loss of $1.4M against $10.7M in annual sales.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.